Physician profile
Donna E Allison
NPI 1679061949
$1,860.03
in general payments reported to CMS, 2019-2025
20 companies · $305 in 2025
The $305 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $351 · 2022: $477 · 2023: $312 · 2024: $415 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $467.69 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $292.78 | 2021-2024 | Airsupra, Farxiga, Fasenra |
| Novo Nordisk INC | $262.47 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $201.64 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $118.63 | 2022-2024 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $86.85 | 2021-2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $67.27 | 2022 | |
| Exact Sciences Corporation | $49.42 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Genentech USA, INC. | $48.19 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.00 | 2024-2025 | Caplyta |
| Pfizer INC. | $33.63 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.41 | 2021-2022 | |
| Dexcom, INC. | $25.32 | 2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $23.95 | 2024 | Rexulti |
| Halozyme INC | $23.54 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $22.65 | 2025 | Auvelity |
| Antares Pharma, INC. | $19.60 | 2024 | Xyosted |
| Merck Sharp & Dohme LLC | $15.94 | 2021 | |
| Abbott Laboratories | $15.88 | 2021 | |
| Inspire Medical Systems, INC. | $15.17 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Allison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.